AMAG's Feraheme gets CMS Q-codes: AMAG Pharmaceuticals' novel I.V. anemia therapyFeraheme (ferumoxytol) brought in about $3 million in third-quarter sales, largely due to launch pilots. But non-dialysis chronic kidney disease providers are buying significantly more product than dialysis organizations, execs said during an Oct. 29 earnings call. "This does not mean that our sales will continue to be weighted towards non-dialysis CKD, but it's indicative of the differences in the sales cycle between the two segments," said Timothy Healey, Senior VP-Commercial Operations. Before switching products, dialysis organizations consider how a drug performs, how it will affect work flow and contractual incentives - reimbursement is crucial since that is how the dialysis businesses get paid. In a positive nod, CMS assigned Feraheme two unique temporary Medicare Q-codes for dialysis and pre-dialysis patients just a few months after the drug gained FDA approval in June (1"The Pink Sheet," July 6, 2009). The Q-codes, effective Jan. 1 2010, will speed reimbursement since they are product-specific and don't require a claim-by-claim manual review
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.
